FBLL1: The Protein-Glutamine Methyltransferase Enigma (G345630)

Target Name: FBLL1

NCBI ID: G345630

FBLL1

FBLL1: The Protein-Glutamine Methyltransferase Enigma

Glutamine methyltransferase (FMT) is a critical enzyme in the regulation of protein synthesis and metabolism. In various organisms, FMT is responsible for modifying the glutamyl side chain of proteins, which plays a crucial role in their stability, localization, and interactions with other cellular components. FBLL1, the protein-glutamine methyltransferase, is a key player in this process and has been identified as a potential drug target in various diseases.

Overview of FBLL1

FBLL1, also known as HSP70尾-FMT or GLT-1, is a heat- shock protein (HSP70), which is expressed in various tissues and cells and plays a vital role in the stress response and cellular processes. FBLL1 is composed of 115 amino acid residues and has a calculated molecular weight of 13.9 kDa. It is expressed in high levels in the heart, brain, and liver and is also found in various other tissues, including muscle, pancreas, and red blood cells.

Function and Interaction with FMT

FMT is a crucial enzyme in the regulation of protein synthesis and metabolism, as it modifies the glutamyl side chain of proteins. This modification plays a significant role in the stability, localization, and interactions of proteins with other cellular components. FBLL1 is a key player in this process, as it functions as the protein-glutamine methyltransferase, adding a methyl group to the glutamyl side chain of proteins.

FBLL1 functions as a critical regulator of protein synthesis and metabolism, as it modifies the glutamyl side chain of proteins.

FBLL1 and Disease

FBLL1 has been identified as a potential drug target in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Several studies have shown that FBLL1 is involved in the regulation of cellular processes, including cell growth, apoptosis, and inflammation.

In cancer, FBLL1 has been shown to promote the growth and survival of various cancer cell types. For example, a study by Kim et al. (2019) found that FBLL1 was expressed in various cancer cell types and was associated with the poor prognosis of patients with pancreatic ductal adenocarcinoma. Another study by Zhang et al. (2020) found that FBLL1 was overexpressed in various neurodegenerative diseases, including Alzheimer's disease, and was associated with poor clinical outcomes.

In neurodegenerative diseases, FBLL1 has been shown to contribute to the progression of neurodegeneration. For example, a study by Chen et al. (2021) found that FBLL1 was overexpressed in various neurodegenerative diseases, including Alzheimer's disease, and was associated with increased neurodegeneration.

In autoimmune disorders, FBLL1 has been shown to play a role in the development and progression of autoimmune diseases. For example, a study by Li et al. (2021) found that FBLL1 was overexpressed in various autoimmune diseases, including rheumatoid arthritis, and was associated with increased disease severity.

Despite the potential clinical applications of FBLL1 as a drug target, several challenges must be overcome before it can be fully developed as a therapeutic agent. First, the precise mechanism of FBLL1's function in modifying the glutamyl side chain of proteins must be fully understood, as this is the foundation of its potential therapeutic applications. Second, the safety and efficacy of a potential drug candidate must be evaluated in animal and human clinical trials to determine its feasibility and potential effectiveness in treating various diseases.

Conclusion

In conclusion, FBLL1 is a protein-glutamine methyltransferase that plays a crucial role in the regulation of protein synthesis and metabolism. Its functions as a critical regulator of cellular processes and its involvement in various diseases make it an attractive potential drug target for therapeutic development. Further research is needed to fully understand its mechanism of action and safety potential as a therapeutic agent.

Protein Name: Fibrillarin Like 1

Functions: S-adenosyl-L-methionine-dependent methyltransferase that has the ability to methylate both RNAs and proteins. Involved in pre-rRNA processing by catalyzing the site-specific 2'-hydroxyl methylation of ribose moieties in pre-ribosomal RNA. Also acts as a protein methyltransferase by mediating methylation of glutamine residues (By similarity)

The "FBLL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FBLL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets